A dual-modal graph learning framework for identifying interaction events among chemical and biotech drugs
暂无分享,去创建一个
[1] Tudor I. Oprea,et al. Novel drug targets in 2022 , 2023, Nature reviews. Drug discovery.
[2] Xiangxiang Zeng,et al. DSN-DDI: an accurate and generalized framework for drug-drug interaction prediction by dual-view representation learning , 2023, Briefings Bioinform..
[3] Xin Dong,et al. Small molecule drug and biotech drug interaction prediction based on multi-modal representation learning , 2022, BMC Bioinformatics.
[4] Kuan-Fu Chen,et al. Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator , 2022, CPT: pharmacometrics & systems pharmacology.
[5] Tudor I. Oprea,et al. Novel drug targets in 2021 , 2022, Nature Reviews Drug Discovery.
[6] Hui Yu,et al. RANEDDI: Relation-aware network embedding for drug-drug interaction prediction , 2022, Inf. Sci..
[7] Jian-Yu Shi,et al. Drug-drug interaction prediction with learnable size-adaptive molecular substructures , 2021, Briefings Bioinform..
[8] Tudor I. Oprea,et al. Novel drug targets in 2020 , 2021, Nature Reviews Drug Discovery.
[9] F. Albericio,et al. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules , 2021, Molecules.
[10] Xin Chen,et al. Multi-view Graph Contrastive Representation Learning for Drug-Drug Interaction Prediction , 2020, WWW.
[11] Jimeng Sun,et al. SumGNN: multi-typed drug interaction prediction via efficient knowledge graph summarization , 2020, Bioinform..
[12] Xiaomin Luo,et al. Pushing the boundaries of molecular representation for drug discovery with graph attention mechanism. , 2020, Journal of medicinal chemistry.
[13] Eytan Ruppin,et al. Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning , 2020, Nature.
[14] Xiangxiang Zeng,et al. KGNN: Knowledge Graph Neural Network for Drug-Drug Interaction Prediction , 2020, IJCAI.
[15] Xiaofeng Wang,et al. Drug–target affinity prediction using graph neural network and contact maps , 2020, RSC advances.
[16] Tudor I. Oprea,et al. Novel drug targets in 2019 , 2020, Nature Reviews Drug Discovery.
[17] Yizhou Sun,et al. Heterogeneous Graph Transformer , 2020, WWW.
[18] F. Albericio,et al. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules , 2020, Molecules.
[19] Jimeng Sun,et al. CASTER: Predicting Drug Interactions with Chemical Substructure Representation , 2019, AAAI.
[20] Tudor I. Oprea,et al. Novel drug targets in 2018 , 2019, Nature reviews. Drug discovery.
[21] Mihai Udrescu,et al. A Drug Repurposing Method Based on Drug-Drug Interaction Networks and Using Energy Model Layouts. , 2018, Methods in molecular biology.
[22] Jure Leskovec,et al. How Powerful are Graph Neural Networks? , 2018, ICLR.
[23] Weilin Huang,et al. Deep Metric Learning with Hierarchical Triplet Loss , 2018, ECCV.
[24] Thorsten Lehr,et al. PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin , 2018, CPT: pharmacometrics & systems pharmacology.
[25] S. Garneau‐Tsodikova,et al. What are the drugs of the future? , 2018, MedChemComm.
[26] Torsten Schwede,et al. SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..
[27] Jae Yong Ryu,et al. Deep learning improves prediction of drug–drug and drug–food interactions , 2018, Proceedings of the National Academy of Sciences.
[28] Jure Leskovec,et al. Modeling polypharmacy side effects with graph convolutional networks , 2018, bioRxiv.
[29] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[30] Gaelen T. Hess,et al. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions , 2017, Nature Biotechnology.
[31] Max Welling,et al. Modeling Relational Data with Graph Convolutional Networks , 2017, ESWC.
[32] Hui Liu,et al. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks , 2016, BMC Bioinformatics.
[33] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.
[34] Naomi S. Altman,et al. Points of Significance: Classification evaluation , 2016, Nature Methods.
[35] Sebastian Nowozin,et al. f-GAN: Training Generative Neural Samplers using Variational Divergence Minimization , 2016, NIPS.
[36] M. Steinman. Polypharmacy-Time to Get Beyond Numbers. , 2016, JAMA internal medicine.
[37] Jocelyn R. Wilder,et al. Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. , 2016, JAMA internal medicine.
[38] Jian Sun,et al. Deep Residual Learning for Image Recognition , 2015, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR).
[39] George Hripcsak,et al. Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.
[40] Markus Gruber,et al. CCMpred—fast and precise prediction of protein residue–residue contacts from correlated mutations , 2014, Bioinform..
[41] Hongkang Mei,et al. Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..
[42] R. Sharan,et al. INDI: a computational framework for inferring drug interactions and their associated recommendations , 2012, Molecular systems biology.
[43] M. Rask-Andersen,et al. Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.
[44] L. Deckelbaum,et al. Effect of nesiritide in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.
[45] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[46] Jiunn H Lin,et al. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. , 2009, Current drug metabolism.
[47] Allen Huang,et al. The challenge of managing drug interactions in elderly people , 2007, The Lancet.
[48] Benno Schwikowski,et al. Graph-based methods for analysing networks in cell biology , 2006, Briefings Bioinform..
[49] L. Rubin. Epoprostenol and nesiritide in pulmonary hypertension. , 2005, Chest.
[50] E. Ernst,et al. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. , 2005, International journal of cardiology.
[51] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[52] G. Jang,et al. Pharmacokinetics and its role in small molecule drug discovery research , 2001, Medicinal research reviews.
[53] L. Korcek,et al. Thyroxine-protein interactions. Interaction of thyroxine and triiodothyronine with human thyroxine-binding globulin. , 1976, The Journal of biological chemistry.
[54] OUP accepted manuscript , 2022, Briefings In Bioinformatics.
[55] Y. Nabuchi,et al. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. , 2009, Drug metabolism and pharmacokinetics.